Back to results
US 8,940,299 B2Granted
Method of treating cancer
AssigneeCase Western Reserve University
InventorsM. Edward Medof, Michael G. Strainic, Young A Choi
Life of this patent
Estimating the term…
Abstract
A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell.
Claims18
A method of inducing apoptosis in a cancer cell expressing a C3a receptor (C3aR) and a C5a receptor (C5aR), the method comprising:
- administering amounts of a C3aR antagonist and a C5aR antagonist directly or locally to the cancer cell;
- wherein the amounts of the C3aR antagonist and the C5aR antagonist administered to the cancer cell are effective to substantially reduce or substantially inhibit the activity of protein kinase B (PKB) in the cancer cell and induce apoptosis in the cancer cell, and wherein the C3aR antagonist inhibits C3a mediated C3aR signaling of the cancer cell and the C5aR antagonist inhibits C5a mediated C5aR signaling of the cancer cell.
A method of treating cancer in a subject, the method comprising:
- administering directly or locally to cancer cells expressing C3aR and C5aR of a subject therapeutically effective amounts of a C3aR antagonist and a C5aR antagonist, wherein the amounts of C3aR antagonist and C5aR antagonist administered to the cancer cells substantially reduce or substantially inhibit the activity of protein kinase B (PKB) in the cancer cells and induce apoptosis in the cancer cells, and wherein the C3aR antagonist inhibits C3a mediated C3aR signaling of the cancer cell and the C5aR antagonist inhibits C5a mediated C5aR signaling of the cancer cell.
A method of treating cancer in a subject, the method comprising:
- administering directly or locally to cancer cells expressing C3aR and C5aR of the subject therapeutically effective amounts of a C3aR antibody and a C5aR antibody to induce apoptosis in the cancer cells, wherein the C3aR antibody inhibits C3a mediated C3aR signaling of the cancer cell and the C5aR antibody inhibits C5a mediated C5aR signaling of the cancer cell.
Dependencies are inferred from the claim text.